Direct secondaries specialist NewQuest Capital Partners has acquired a minority stake in Cloudnine, an India-based hospital chain, by committing primary capital and taking out several existing investors.
TransThera, a China-based drug developer, has raised $100 million in Series D funding led by CPE and China Structural Reform Fund.
PAG has acquired a controlling stake in Acme Formulation Private, an India-based contract development and manufacturing organization (CDMO), for approximately $145 million.
Chinese next-generation sequencing (NGS) player Geneplus Technology has raised a RMB750 million ($116 million) Series C round led by China Construction Bank’s venture unit CCB International.
Five VC-backed pre-revenue Chinese biotech companies have filed to list in Hong Kong over the past two weeks, doubling the size of the IPO pipeline in this category.
LeapFrong Investments and Khosla Ventures have led a $75 million Series C round for HealthifyMe, a mobile health and fitness app operator with a presence in India and Southeast Asia.
Beauty and wellness are at the vanguard of China’s fast-rising services sector. Investors see clear paths to growth, but size presents a plethora of problems in terms of standardizing service quality
China’s Meiwei Dental Group has raised a RMB1 billion ($150 million) Series B round from Fortune Capital, TFTR Investment, and local conglomerate New Hope Group.
Sherpa Healthcare Partners has led a $30 million Series A for Paq Therapeutics, a Chinese-founded biotech company specializing in treatments based on molecules that enhance the degradation of disease-causing entities.
Silicon Valley-based NewView Capital has led a A$30 million ($22.4 million) Series B round for Australia telehealth platform Eucalyptus.
Adlai Nortye, a Chinese biopharma player specializing in cancer treatments, has raised $100 million in Series D funding.
The GP spent six months scrutinizing China’s Linkedcare prior to leading a $70 million round, confident that its global insights into software, healthcare, and supply chains were key differentiators
TE Asia Healthcare Partners, a Southeast Asia-focused investor backed by TPG Capital, has launched a long-term plan to add much-needed cardiology hospitals to Indonesia’s healthcare mix
Unison Capital hones its game and holds tight to its heritage as one of the pioneers of private equity in Japan, even as its tentacles begin to span the breadth of Asia
Synyi.AI - a Chinese provider of artificial intelligence-enabled medical services - has raised RMB500 million ($77 million) in Series E funding led by IDG Capital.
Eight Roads Ventures has promoted Ashish Venkataramani to partner in India. It brings the firm's partner count across Bangalore and Mumbai to five.
DMed-Clinipace, a global contract research organization (CRO) with a presence in China, has raised $50 million in an extended Series C round led by Springhill Fund. Rock Springs Capital and Superstring Capital also took part.
TE Asia Healthcare Partners, a Singapore-based hospital platform backed by TPG Capital, has acquired controlling stakes in two Indonesian cardiology centers.
Qiming Venture Partners is mobilizing its newly launched public equities unit – and $500 million fund – to participate as an anchor investor in Hong Kong IPOs by Chinese healthcare companies.
Arrail Group, a leading Chinese dental chain that has raised about $400 million in private funding since 2010, has filed for a Hong Kong IPO.
A consortium led by healthcare-focused Quadria Capital has invested in Indian topical drugs maker Encube Ethicals, facilitating an exit for Multiples Alternate Asset Management.
Fidelity-backed Eight Roads has launched a China healthcare fund with a corpus of $400 million, which will invest across the industry value chain and in areas related to critical diseases.
HutchMed – formerly Hutchison China MediTech – saw its share price jump 50% on debut after raising HK$4.17 billion ($536.9 million) through a Hong Kong share offering.
Linkedcare, a software-as-a-service (SaaS) and supply chain provider to China's healthcare sector, has closed a Series D funding round. Including an earlier Series C extension, the company claims to have raised $100 million in the past six months.